Preclinical News and Research

RSS

FDA approves trial for SKCC breast cancer vaccine

The Federal Drug Administration announced Friday approval of a Phase 1 clinical trial designed to study a breast cancer vaccine developed at the Sidney Kimmel Cancer Center.

10 Dec 2007

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.

4 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

Purified bacterial extract sprayed into lungs ramps up innate immune system

A purified extract prepared from a common microbe and delivered to the lungs of laboratory mice in a spray set off a healthy immune response and provided powerful protection against all four major classes of pathogens including those responsible for anthrax and bubonic plague, according to a presentation at the American Society for Cell Biology's 47th Annual Meeting.

4 Dec 2007

Inhaled immune system stimulant launches immune response in lungs to wipe out lethal infections

An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.

4 Dec 2007

Vaccinex receives new European patent for antibody discovery technology

Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.

3 Dec 2007

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

2 Dec 2007

AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (anastrozole)

AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010.

2 Dec 2007

Sirtris Pharmaceuticals unveils promising, novel SIRT1 activators for treating diseases of aging

Sirtris Pharmaceuticals has announced that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.

29 Nov 2007

Innovative drug production project secures funding from Technology Strategy Board

PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, has announced that it has secured funding from the Technology Strategy Board.

29 Nov 2007

BioMarin files investigational NDA for PEG-PAL for the treatment of phenylketonuria

BioMarin Pharmaceutical Inc. has announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL (Poly Ethylene Glycol-Phenylalanine Ammonia Lyase), formerly known as Phenylase, for the treatment of phenylketonuria (PKU).

27 Nov 2007

New drug called nitrosyl-cobinamide could potentially be used to treat hypertension and heart disease

Investigators at the University of California, San Diego School of Medicine have developed a new drug called nitrosyl-cobinamide.

27 Nov 2007

New non-addictive pain-killers

Two University of Adelaide pharmacologists working with one the world's leading neuroscientists have helped pave the way for the development of new pain-killing drugs that are not addictive.

20 Nov 2007

Gene-transfer technique trial for childhood blindness under way

Three decades have passed since gene therapy pioneer William W. Hauswirth, Ph.D., and his colleagues at the University of Florida began work on a virus that could safely deliver corrective genes into living animals.

19 Nov 2007

Some viral-vector vaccines may cause more harm than good

Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has emerged that some of these so-called viral vector systems may undermine the immune system and should not be used for vaccine development.

16 Nov 2007

Nitrite/nitrate-rich foods may help in heart attack survival

Nitrite/nitrate found in vegetables, cured meats and drinking water may help you survive a heart attack and recover quicker, according to a pre-clinical study led by a cardiovascular physiologist at The University of Texas Health Science Center at Houston.

13 Nov 2007

CellCyte Genetics receives patent on stem cell delivery method

CellCyte Genetics Corporation has announced that is has received notice of the issuance of a U.S. patent (U.S. Patent No. 7,282,222) for its unique methods and compositions approach to deliver and direct stem cells to target organs in the body.

13 Nov 2007

Lexicon files investigational NDA for LX2931 in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.

13 Nov 2007

D-cycloserine could help treat drug addiction

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory provide further evidence that a drug known as D-cycloserine could play a role in helping to extinguish the craving behaviors associated with drug addiction.

6 Nov 2007